CD274 and neoplasm: PD‐L1 has been identified as a key regulator of immune evasion that ultimately leads to immune tolerance and further deterioration of tumor.[7] Accumulating evidences have suggested that CRISPR/Cas9 regulating expression of PD‐L1 can contribute to activation of adaptive immunity, but the outcome of monotherapy targeted to PD‐L1 would be compromised by the low immune response of tumor cells.